Corium International — Technical Presentation (May 2017)
21 slides from Corium International's technical presentation, May 11, 2017
Slide 1: Corplex Donepezil Pilot Bioequivalence Study Preliminary Results
Corplex Donepezil® Pilot Bioequivalence Study Preliminary Results May 11, 2017
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Study Objectives and Preliminary Results
Study Objectives and Preliminary Results Determine optimal patch size for Pivotal Bioequivalence (BE) Trial Establish intra-subject variability of AUC and Cmax Determine optimal number of subjects required in Pivotal BE Trial Demonstrate acceptable skin and gastrointestinal tolerability Demonstrate
Slide 4: Preliminary Conclusion
Preliminary Conclusion Although not an objective of this study, statistical bioequivalence was achieved
Slide 5: Donepezil Pilot Study: Overall Design and Timing
Donepezil Pilot Study: Overall Design and Timing Three period, three-treatment, randomized crossover study Period 1 Period 2 Period 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ← Screening → PK PK PK Cohort 1 (20 subjects start) 5mg 10mg Aricept Oral Washout 5mg 10mg
Slide 6: Subject Demographics
Subject Demographics Demographic Distribution Age 20-78 years Male/Female 57% / 43% Non-Hispanic Caucasian/ Hispanic 75% / 25% 60 healthy volunteers enrolled at beginning of study Very low attrition: 50 completed the study >80% were more than 40 years old *At study initiation 4 6 15 23 9 3 20-30 31-
Slide 7: Donepezil Projected Steady State PK Profile
Donepezil Projected Steady State PK Profile Solid Lines = Actual Phase 1 PK Data (Week 1) * Projections based on one-week PK study (September 2016, n=6) of Corplex Donepezil and one week PK study (June 2016, n=6) of oral Aricept Projected PK at Steady State
Slide 8: Observed PK Profiles at Steady State
Observed PK Profiles at Steady State Oral PK measured only on Day 7 Plasma sampling for patch treatments taken throughout Week 5 Plasma sampling for Aricept taken only on last day (day 7) of Week 5 Transdermal Delivery Exhibits Similar PK Profile to Oral Aricept Patch A and B exhibit dose proportion
Slide 9: Bioequivalence Assessment of Patch A
Bioequivalence Assessment of Patch A Primary PK Parameters Geometric Mean Ratio (%) (Patch A vs. Oral Aricept) BE Limits (Target 80-125%) AUCss (ng-hr/ml) 104.7 95.2 - 115.2 Cmaxss (ng/ml) 91.6 83.1 - 100.8 *AUCss - area under the curve at steady state (for patch, observed area under the curve throu
Slide 10: Bioequivalence Assessment (Patch A)
Bioequivalence Assessment (Patch A) Primary PK Supportive PK** 125 80 Cmax AUCweek * At 90% confidence intervals The 80 – 125% criteria do not apply to supportive PK parameters; FDA has indicated that these will be tested for “no significant difference” compared to oral Aricept ** % Fluctuation data
Slide 11: Most Common GI Side Effects
Most Common GI* Side Effects * GI = Gastrointestinal Patch A incidence of nausea was more than 4x less than Aricept 4 2 4 10 13 2 7 12 17 5 9 12 0 2 4 6 8 10 12 14 16 18 Nausea Vomiting Diarrhea Constipation Number of Subjects GI Related Adverse Events, by Subject Count Patch A (n=54) Patch B (n=55)
Slide 12: Favorable Skin Tolerability
Favorable Skin Tolerability * Score on a rating scale of 0 (none) to 7 (strong reaction beyond patch application site) per FDA draft guidance on dermal response Percentage of patches exhibiting no irritation (score of 0) are not displayed in chart above Observed Skin Irritation (based on 340 applica
Slide 13: Favorable Skin Adhesion
Favorable Skin Adhesion Adhesion Score Adhered Portion(%) Observed Frequency(%) 0 100 65.9 1 ≥ 90 27.8 2 ≥ 80 4.4 3 ≥ 70 1.4 4 ≥ 60 0.2 5 ≥ 50 None 6 < 50 0.3 * Mean adhesion score derived from individual adhesion scores taken every 12 hours over the course of each one week treatment with Patch A an
Slide 14: Patch A Wearability: Thin and Flexible
Patch A Wearability: Thin and Flexible ~150cm2 Delivers 7 Days of Drug Thinner Than a Dime
Slide 15: No Apparent BMI or Age Effects
No Apparent BMI* or Age Effects No Apparent Effect of BMI or Age on AUCweek *BMI = Body Mass Index 20 30 40 50 60 70 80 Age (years) 18 20 22 24 26 28 30 32 AUC week BMI (kg/m 2 )
Slide 16: Next Steps
Finalize patch size for use in Pivotal Study (~11cm x 14cm) Manufacture three lots of final patch at 10% commercial batch scale Put samples from all three lots on long-term stability testing Meet with FDA this summer to reconfirm finalized study parameters Commence Pivotal Study in September/October
Slide 17: Pivotal Study Design More Streamlined
Pilot Pivotal 3-way crossover, randomized 2-way crossover, randomized Healthy Volunteers Healthy Volunteers Enroll 60 to complete at least 30 (50 actually completed) Enroll 64-100 to complete 54-86 (to be finalized mid-June) 3 treatments (2 patch sizes and oral Aricept) 2 treatments (Final patch siz
Slide 18: Donepezil Pivotal Study Design
Donepezil Pivotal Study Design Each subject will be randomized into one of two treatment sequences Period 1 Period 2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 PK PK Cohort 1 Screening 5mg Oral 10mg Aricept Oral Extended Washout 5mg Patch 10mg Final Patch Follow-Up PK PK Cohort 2
Slide 19: Expected Donepezil Pathway to Commercialization
Expected Donepezil Pathway to Commercialization 2016 2017 2018 2019 2020 2021 Pilot BE Study Pivotal BE Study File NDA Commercialize Patch A Achieved Bioequivalence Section 505(b)(2) File in 2H 2018 PDUFA in 2H 2019 U.S. Launch in 2H 2019 EU in 2020/2021 Japan in 2022 Two-way Crossover Start in Sept
Slide 20: Study Objectives and Preliminary Results
Study Objectives and Preliminary Results Determine optimal patch size for Pivotal BE Trial Establish intra-subject variability of AUC and Cmax Determine optimal number of subjects required in Pivotal BE Trial Demonstrate acceptable skin and gastrointestinal tolerability Demonstrate acceptable adhesi
Slide 21: Thank You
Thank You Nasdaq: CORI Corium
Corium International — Technical Presentation (May 2017) on 6ix